Tesamorelin and Ipamorelin are both growth hormone secretagogues, but they work through entirely different receptor pathways and are optimized for different clinical goals. Understanding these differences is essential for choosing the right peptide — or deciding whether to use both together.
How They Work
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid human GHRH sequence with a trans-3-hexenoic acid modification for enhanced stability. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the physiological synthesis and pulsatile release of endogenous growth hormone. The resulting GH elevation drives lipolysis — particularly in visceral adipose tissue — while preserving lean mass. It is the only GH-releasing peptide with FDA approval (Egrifta, for HIV-associated lipodystrophy).
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Unlike other ghrelin mimetics (GHRP-6, GHRP-2), Ipamorelin stimulates GH release without significantly elevating cortisol, prolactin, or appetite — even at supraphysiological doses. This selectivity makes it the best-tolerated GH peptide in its class. It is commonly stacked with CJC-1295 (Mod GRF 1-29) for amplified GH pulses.
What the Research Shows
Tesamorelin has the strongest clinical data of any GH-releasing peptide. Pivotal trials in HIV-associated lipodystrophy demonstrated significant reductions in visceral adipose tissue, improvements in trunk fat percentage, and favorable changes in liver fat and lipid profiles. Long-term extension studies (52+ weeks) confirmed sustained efficacy and safety. Off-label, it is increasingly used for body composition optimization and metabolic health.
Ipamorelin's clinical data, while less extensive, clearly establishes its selective GH-releasing profile. Phase 1 studies demonstrate dose-dependent GH elevation with a clean safety profile. Clinical trials in postoperative ileus confirmed its GH-releasing properties in a patient population. Its real-world use is extensive in anti-aging and sports medicine, though it lacks the large-scale randomized trials that support Tesamorelin.
Side Effects and Tolerability
Tesamorelin side effects are related to its potent GH elevation: arthralgia (joint pain), peripheral edema, paresthesia (tingling), and injection site reactions. These are dose-dependent and generally manageable. Monitoring IGF-1 levels is recommended every 3-6 months.
Ipamorelin is remarkably well-tolerated. Side effects are mild and infrequent — headache, transient water retention, and occasional lightheadedness post-injection. It does not increase appetite (unlike GHRP-6) or cortisol, making it suitable for patients sensitive to hormonal fluctuations.
Cost Comparison
Tesamorelin is the more expensive option at $300-600/month through compounding pharmacies (branded Egrifta is significantly more). Ipamorelin is considerably more affordable at $100-250/month, especially when purchased as a compounded peptide.
How to Choose
Choose Tesamorelin if: your primary goal is visceral fat reduction and body composition improvement. It is the only FDA-approved option in this class and has the most robust clinical data for fat loss. It is also the better choice if liver health (reducing hepatic steatosis) is a concern.
Choose Ipamorelin if: you want general GH optimization for anti-aging, recovery, sleep quality, and body composition. Its clean side-effect profile, flexible dosing, synergy with CJC-1295, and lower cost make it the most versatile GH peptide for broad optimization. It is the standard starting point for most GH peptide protocols.
Consider combining both if: you want maximum GH stimulation through dual-pathway activation. This is an advanced protocol that requires physician supervision and regular IGF-1 monitoring to avoid supraphysiological GH exposure.